Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations

Endocrine Practice

Volumn 17, Issue 2, 2011, Pages 192-200

  Varanasi, Ajay ^a   Chaudhuri, Ajay ^a   Dhindsa, Sandeep ^a   Arora, Amita ^a   Lohano, Teekam ^a   Vora, Mehul R ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TERTIARY HEALTH CARE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VENOMS;

EID: 79959243823     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10199.OR     Document Type: Article

References (16)

1. Amori RE, Lau J, Pittas AG. Effcacy and safety of incre-tin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206. (Pubitemid 47057766)
2. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glyce-mic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370-2377. (Pubitemid 36993328)
3. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-450.
4. Hirata K, Kume S, Araki S, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380:44-49.
5. Laugero KD, Stonehouse AH, Guss S, Landry J, Vu C, Parkes DG. Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord. 2009;7:327-334.
6. Mafong DD, Henry RR. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009;11:18-22.
7. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.
8. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143:559-569.
9. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31:1511-1523.
10. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139-153. (Pubitemid 46414034)
11. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846-E852.
12. Linnebjerg H, Park S, Kothare PA, et al. Effect of exena-tide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-129.
13. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23:334-339.
14. Dandona P, Chaudhuri A, Dhindsa S. A novel anti-hypertensive effect of exenatide, a GLP-1 agonist. Am J Hypertens. 2010;23:228.
15. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010;33:1028-1030.
16. Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med. 2010;122:118-128.